Skip to main content
. 2021 Jan 11;11:609941. doi: 10.3389/fimmu.2020.609941

Figure 3.

Figure 3

Binding stability of CD20 mAbs across different lymphoma B cell lines. (A) Dissociation after incubation with 60 nM fluorescein isothiocyanate Rituximab (FITC-RTX) in either plain medium (solid lines) or in the presence of 60 nM unlabeled RTX (dashed lines). (B) Dissociation after incubation with 10 nM, 30 nM or 60 nM FITC-RTX in the presence of equimolar amounts of unlabeled RTX. (C) Dissociation in plain medium after incubation with either 10 nM (dashed lines) or 60 nM (solid lines) FITC-RTX-Fab. (D) Dissociation after incubation with 60 nM FITC-RTX-Fab in either plain medium (solid lines) or presence of 60 nM unlabeled RTX-Fab (dashed lines). (E) Dissociation after incubation with 60 nM FITC-Obinutuzumab (OBI) in either plain medium (solid lines) or in the presence of 60 nM unlabeled OBI (dashed lines). (F) Dissociation after incubation with 60 nM FITC-Ofatumumab (OFA) in the presence of 180 nM unlabeled OFA. Note the different y-axis scaling. (G) Average half-life for bound OFA calculated from data shown in (F). Bars represent mean ± standard deviation of n=3–4 independent measurements.